Lunaphore Receives Additional CHF2M in Series C2 Funding

lunaphore

Lunaphore Technologies, a Lausanne, Switzerland – based life-sciences company developing innovative next – generation equipment for cancer research and tissue diagnostics, raised CHF 2M in Series C2 financing.

The Series C2 financing was provided by the Swiss Entrepreneurs Fund, which invested a total of CHF 5M in the company. The second closing brought the total Series C round to CHF 25M.

The company intends to use the funds for market and product expansion, including a US market entry, the ramp up of activities in Europe and the development of next generation of instruments.

Founded in 2014, Lunaphore Technologies is developing next generation tissue autostainers. The microfluidics based technology – called FFeX (Fast Fluidic Exchange) – aims to perform assays much faster than standard techniques and has demonstrated good results in tests with cancer patient samples.

FinSMEs

23/04/2020

Join the discussion